Purpose The pharmacokinetic proWles of bendamustine and active metabolites were deWned in patients with rituximab-refractory, relapsed indolent B-cell non-Hodgkin's lymphoma, and supported understanding of exposureresponse relationships for eYcacy and safety. Methods Bendamustine was administered as a 60-min 120 mg/m 2 intravenous infusion on days 1 and 2 of six 21-day cycles. Pharmacokinetic models were developed, with covariate assessment. Correlations between bendamustine exposure and responder status or occurrence of neutropenia, thrombocytopenia, fatigue, nausea, and vomiting were examined.
Introduction
Bendamustine (Treanda ® , Cephalon, Inc., Frazer, PA, USA) is a novel chemotherapeutic agent comprised of a bifunctional mechlorethamine alkylating group, a purinelike benzimidazole ring, and a butyric acid side chain. The drug has been shown to be a potent cytotoxic agent, with in vitro studies demonstrating extensive and durable DNA damage [1, 2] . In addition to direct DNA damage and apoptosis, other mechanisms for bendamustine action include inhibition of mitotic checkpoints and induction of mitotic catastrophe [1] . These mechanistic characteristics may explain bendamustine's activity in drug-resistant cancer cells and refractory lymphoma patients [2, 3] . The contribution of the benzimidazole group to the overall anti-tumor activity of bendamustine is not currently known.
This agent has shown clinical activity against various hematologic malignancies and has been commercially available in Germany for many years [3] [4] [5] [6] [7] . Bendamustine was recently approved for marketing by the US Food and Drug Administration for chronic lymphocytic leukemia (CLL) and indolent non-Hodgkin's lymphoma (NHL) that has progressed during or within 6 months of treatment with rituximab or a rituximab-containing regimen. In a Phase 2 trial of bendamustine monotherapy for rituximab-refractory indolent (80%) and transformed (20%) NHL, the most frequent non-hematologic adverse eVects included nausea, vomiting, fatigue, and constipation [3] . Grade 3 or 4 reversible hematologic toxicities included neutropenia (54%), thrombocytopenia (24%), and anemia (12%).
The primary route of bendamustine metabolism in humans is hydrolysis to the inactive metabolites monohydroxy (HP1) and dihydroxy (HP2) bendamustine. Two metabolites of bendamustine (gamma-OH-bendamustine (M3) and N-desmethyl-bendamustine (M4)) have cytotoxic activity and are formed via the minor CYP1A2 oxidative pathway [8] . Relative potency was considered 1/5 for M4 and 1 for M3, compared to bendamustine [8] . Bendamustine is >95% protein bound, but this binding is not aVected by age (>70 years), low serum albumin levels (<31 g/L), or the presence of advanced tumors (data on Wle, Cephalon, Inc).
Although bendamustine has been in clinical use for many years, little information has been published regarding the pharmacokinetics (PK) of bendamustine. The goals of these analyses were to deWne the PK proWle for bendamustine and its two active metabolites based on data obtained from patients with indolent NHL refractory to rituximab. Individual patient estimates of bendamustine exposure [area under the plasma concentration versus time curve (AUC) and maximum plasma concentration (C max )] were generated using the PK model to perform exposure-response analyses characterizing the eYcacy (duration of response, progression-free survival) and safety (occurrence of neutropenia, fatigue, nausea, and vomiting) of bendamustine in these patients. Factors inXuencing either the PK of bendamustine or response to this therapy were also assessed.
Materials and methods
Study design, blood sampling, and bioanalysis Data were obtained from a Phase 3, multicenter, open-label, 6-treatment cycle, single-agent study designed to investigate the safety, eYcacy, and PK proWle of bendamustine in patients with indolent NHL refractory to rituximab treatment [9] . Patients were men and women at least 18 years of age who had a World Health Organization (WHO) performance score of 0 through 2 [10] . Patients had adequate liver function (·2.5 £ upper limit laboratory normal for AST (SGOT), ALT (SCPT), and alkaline phosphatase, ·1.5 £ upper limit laboratory normal for total bilirubin). Estimated creatinine clearance was greater than 30 mL/ min, [11] and an absolute neutrophil count of greater than 1,000 cell/mm 3 . Patients included in the analyses had NHL in the WHO classiWcations of small lymphocytic lymphoma, lymphoplasmacytic lymphoma, splenic marginal zone B-cell lymphoma (with or without villous lymphocytes), extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type, nodal marginal zone lymphoma (with or without monocytoid B cells), and follicular lymphoma.
All studies were conducted in accordance with the principles of the Declaration of Helsinki and were approved by the Human Investigational Review Board of each study center. Informed consent was obtained from each subject after explanation of the potential risks and beneWts, as well as the investigational nature of the study.
Bendamustine was administered as a 60-min intravenous (IV) infusion at a dose of 120 mg/m 2 on day 1 and day 2 of six consecutive 21-day treatment cycles. A dose reduction was required for study drug-related grade 4 hematologic toxicity or grade 3 or 4 non-hematologic toxicity [12] . The 120 mg/m 2 dose was selected based on previous ex vivo studies indicating that the median lethal dose for bendamustine in CLL cells produces concentrations ranging from 4.3 to 7.4 g/mL [13] .
Sparse samples (up to 4 per patient) for PK analysis were collected from eighty-eight patients within the following time windows on day 1 or day 2 of cycle 1 or cycle 2: before infusion and at 0.25 to 0.5, 0.5 to <1, 1 to <3, 3 to <7, and 7 to <10 h after infusion. In addition, full PK proWles were obtained in a subset (n = 12) of the patient population at the following time points in cycle 1: immediately before start of the IV infusion, at 30 min after start of infusion, at end of infusion (1 h), and post infusion at 15, 30, and 45 min and 1, 2, 3, 4, 6, 8, 10, 12, 16, 20 , and 24 h. Sparse sampling was also performed in this subset (n = 12) of the patient population within the following time windows in cycle 2: immediately before start of the IV infusion and more than 0.25 to <0.5 h and more than 1 to <3 h after start of infusion.
Whole blood (5 mL) was drawn into evacuated tubes containing EDTA and immediately placed on ice. Within 30 min, samples were centrifuged at 2,000 rpm for 10 min at 4°C, and plasma withdrawn. Within 30 min of separation, plasma samples were transferred to a freezer at ¡20°C until shipment.
Plasma concentrations of bendamustine, M3, and M4 were determined by validated high-performance liquid chromatography tandem mass spectrometry (HPLC MS/ MS) methodology. The lower limit of quantiWcation (LLOQ) was 0.10 ng/mL for bendamustine and M4, and 0.11 ng/mL for M3. The inter-day coeYcients of variation for the assay of bendamustine, M3, and M4 metabolite concentrations were ·10.9, ·12.3, and ·9.2%, respectively.
EYcacy response measures
Assessment of NHL was performed within 28 days before cycle 1, day 1 (baseline), and at week 6, week 12, and every 12 weeks thereafter until the patient completed or discontinued treatment. The end-of-treatment scan was performed within 28 days after the last dose of study drug unless the patient had experienced a delay due to toxicity, in which case the evaluation was performed within 2 weeks of the decision to withdraw the patient from treatment.
The International Workshop Response Criteria (IWRC) for NHL was used to classify each patient's response to bendamustine treatment [14] . Minor modiWcations were made to these criteria in order to clarify certain parameters that were not fully deWned in the published criteria. Assessments were based on computed tomography scans of neck, chest, abdomen, and pelvis, plus palpation of lymph nodes and organs, and assessments of lactate dehydrogenase and bone marrow involvement. Response at each assessment was classiWed as: complete response (CR), complete response/unconWrmed (CRu), partial response (PR), stable disease, relapsed disease (RD), or progressive disease. Best response was deWned as the best tumor outcome assessment observed for a patient (CR, CRu, or PR). Responder patients were deWned as those patients who achieved a best response during the study according to the IWRC for NHL based on the response assessments provided by an independent review committee.
Duration of response (DR) was deWned as the interval from the date of Wrst observation of a response (CR, CRu, or PR) until the date of progression, change of therapy, or death. Progression-free survival (PFS) was deWned as the time interval from the date of Wrst study drug dose to the Wrst documentation of disease progression, change of therapy, or death regardless of cause.
Safety response measures
Safety endpoints of interest included neutropenia, thrombocytopenia, nausea, vomiting, and fatigue. The occurrence of any of these adverse events included any instance reported during treatment (observed events from the start of the Wrst dose until 28 days after the last dose) and classiWed as deWnitely, possibly, or probably related to study medication.
Neutropenia and thrombocytopenia were determined based on weekly laboratory hematology measurements. For each patient cycle, the lowest laboratory absolute neutrophil counts (ANC) measurement was graded based on Common Terminology Criteria for Adverse Events, version 3.0 [12] . Only patients with a grade of 3 or 4 were classiWed as having neutropenia or thrombocytopenia in this analysis. Cytokine use was discouraged for the Wrst cycle to stimulate WBC production, but was allowed in any patient who demonstrated a need for their use.
Statistical methods and population pharmacokinetic model development Population PK and pharmacokinetic/pharmacodynamic (PK/PD) analyses were performed using NONMEM software, version 6, level 1.0 [15] . First-order conditional estimation (FOCE) was used for PK models and Laplacian estimation with the LIKELIHOOD option was used for PK/ PD models.
Separate population PK models were developed for bendamustine, M3, and M4. The population PK models were developed using an index dataset, evaluated using a smaller test dataset, and then the model parameters were re-estimated using a total dataset. For brevity, since the test performance was adequate, this manuscript will detail only the Wnal models.
The PK proWle for bendamustine plasma concentrations declined from peak in a triphasic manner. A three-compartment model was parameterized using central clearance (CL), central (V c ) and peripheral compartment volumes of distribution (V p1 , V p2 ), and intercompartmental clearances (Q 1 , Q 2 ). For M3 and M4, one-and two-compartment models were evaluated with zero-order input following a lag time. Interindividual variability (IIV) and residual variability (RV) were described using an exponential and a proportional error model, respectively. Point estimates of half-life were obtained algebraically using the Wnal, typical parameters of the model.
Covariate analysis was performed for bendamustine only, using a forward selection ( = 0.05) followed by backward elimination ( = 0.001) process. Patient covariates explored included sex, age, race, weight, body surface area (BSA), creatinine clearance (CrCL) (modiWed by the use of ideal body weight (IBW), as proposed by Peck), and concentrations of alanine aminotransferase, aspartate aminotransferase, total bilirubin, and serum albumin [11, 16, 17] .
Model qualiWcation through assessment of predictive performance was conducted. The Wt of the model to the data was evaluated graphically and through measurements of prediction error. The diVerences between the measured and predicted bendamustine concentrations were evaluated for bias (percent individual prediction error (%IPE)) and precision (absolute percent individual prediction error (|%IPE|)) according to the methods of Sheiner and Beal [18] .
In addition, the Wnal model for bendamustine was evaluated using a simulation-based predictive check method. A visual predictive check (VPC) was performed generating 100 simulations from the Wnal model. An overlay of the original data on a prediction interval based on the simulated replicate datasets was prepared.
Determination of exposure measures
Bayesian estimates of PK model parameters for each patient were generated and used to compute measures of exposure. These exposure measures included bendamustine, M3, and M4 cycle 1 AUC and cycle 1 C max , as well as composite AUC and C max . Composite measures were weighted sums of the exposures based on the potency of the moiety.
Summary statistics of exposure measures (i.e., AUC and C max ) were evaluated by categories of sex, age, race, BSA, hepatic function, and renal function. Age was classiWed into three categories: 16-64 years, 65-74 years, and greater than or equal to 75 years. Body surface area was classiWed into quartiles. ClassiWcations for hepatic function were deWned as: normal [total bilirubin and aspartate aminotransferase (AST) ·upper limit of normal (ULN)], mild (total bilirubin >ULN to 1.5 £ ULN or AST > ULN), moderate (total bilirubin >1.5 to 3 £ ULN, any AST), and severe (total bilirubin >3 £ ULN, any AST) [19] . ClassiWcations for renal function were deWned as: normal (CrCL > 80 mL/ min), mild renal impairment (50 mL/min < CrCL · 80 mL/ min), moderate renal impairment (30 mL/min < CrCL · 50 mL/min), and severe renal impairment (CrCL · 30 mL/min) [20] .
Exposure-response model development
Logistic regression analysis was used to statistically assess the relationship between various exposure measures and covariates and responder status or the occurrence of adverse events (fatigue, nausea, and/or vomiting). Residual variability was considered using an additive error structure. Although the protocol allowed for bendamustine dose reduction due to adverse events, statistical comparison of bendamustine, M3, M4, or composite exposures in patients requiring dose reduction relative to those without dose reduction was not performed as no relationship was observed during exploratory graphical assessment.
The inXuence of various covariates was only examined for the exposure measure with the most signiWcant relationship with responder status or the occurrence of fatigue, nausea, or vomiting. The following covariates were evaluated in the exposure-response analyses: sex, age, race, BSA, number of prior treatment courses (non-bendamustine; at baseline), indolent NHL subtype, and WHO performance grade. Prophylactic antiemetic use was also allowed in this clinical trial and was considered for the covariate assessment.
Diagnostic plots were evaluated to determine whether the functional form of the relationship between the estimated logit parameter and the covariate was linear. Non-linear functional forms of continuous covariates were transformed or grouped to meet the linear logit assumption.
A univariate analysis of each patient covariate was performed. Each patient covariate was added to the new base logistic regression model, one at a time, and was tested for signiWcance using a likelihood ratio test ( = 0.05).
Graphical analysis of duration of response and progression-free survival
The relationships between measures of exposure and eYcacy response were explored graphically. Displays of DR and PFS versus exposure stratiWed by the covariates of interest including sex, age, race, number of prior treatment courses, and indolent NHL subtype were constructed. Kaplan-Meier plots of DR (responders only) and PFS were constructed by categorizing each exposure into two groups using the median exposure measure.
Results

Pharmacokinetic data
The total dataset consisted of 347 bendamustine plasma concentrations from 78 subjects, 302 M3 plasma concentrations from 77 subjects, and 254 M4 plasma concentrations from 74 subjects. The data from 22 subjects were removed as their PK samples were assayed outside the validated stability period. Patient characteristics for the total dataset stratiWed by analyte are presented in Table 1 .
Bendamustine population pharmacokinetic model
A three-compartment, open model with zero-order input, Wrst-order elimination, and IIV terms on CL, Vc, Vp1, and Vp2 reasonably described the plasma concentration data for bendamustine. Residual variability was expressed with a proportional error model. No covariate factors were found to signiWcantly inXuence the observed variability in the PK of bendamustine. A schematic diagram of the Wnal bendamustine model is shown in Fig. 1 .
The population PK parameters are shown in Table 2 . The population estimate for clearance of bendamustine (31.7 L/h) was similar to that reported previously in patients with chronic lymphocytic leukemia and solid tumors (approximately 27 L/h/1.73 m 2 ) based on noncompartmental PK analysis [21, 22] . The overall volume of distribution reported here (approximately 40 L) is larger than reported previously (approximately 20 L); however, the duration of full-proWle post-dose PK sampling after bendamustine administration was limited in previous investigations.
Estimates of t 1/2 , t 1/2 , and t 1/2 for bendamustine were 0.29, 0.7, and 110 h, respectively, consistent with a rapid distribution phase, intermediate phase, and a slow terminal decline of plasma concentrations after a single intravenous dose. The AUC for the terminal phase accounted for less than 1% of the total AUC. Therefore, the t 1/2 of the phase is considered to be reXective of bendamustine elimination half-life. Further, the predicted concentration at 12 h (C 12 ) after the Wrst dose was 0.27 ng/mL. The ratio of C 12 to C max had a mean value of 1:25,000. Thus, accumulation is not expected and the single-dose PK proWle is considered representative of the multiple-dose proWle. The median AUC and C max for bendamustine were 13,635 ng £ h/mL and 5,839 ng/mL, respectively.
The mean and median values of %IPE and |%IPE| (6.5 and 18.2%, respectively) measures demonstrated that the model was essentially unbiased and had a reasonable predictive performance. Observed bendamustine concentrations overlaid with median typical value populationpredicted concentrations (Fig. 2) indicate that the model adequately described the central tendencies in the bendamustine concentration-time data.
In addition, a VPC was performed using the Wnal pharmacokinetic model, simulating 100 replications of the analysis dataset. Figure 3 illustrates the 90% prediction interval, derived from the 100 simulated datasets, overlaid on the observed bendamustine concentration versus time relative to dosing data. The majority of the observed sparse data falls within the prediction interval. Overall, the VPC indicates no apparent biases in the overall model Wt by comparing the simulated data (based on the model) to the observed data.
Metabolite population pharmacokinetic models
The population PK models for M3 and M4 were a two-and one-compartment model, respectively (Table 2) . Schematic diagrams of the Wnal models for M3 and M4 are shown in Fig. 1 . The estimated values of M3 t 1/2 and t 1/2 were 0.41 and 2.80 h, respectively, the estimated t 1/2 of M4 was 0.62 h, which was similar to that of the phase of bendamustine. The median M3 and M4 AUC values were 1,252 and 115 ng h/mL, or approximately one-tenth and one-hundredth that of bendamustine, respectively.
Observed M3 concentrations overlaid with median typical value population-predicted concentrations (Fig. 4 , upper 
Determination of exposure
Individual patient exposures (AUC and C max ) for bendamustine, M3, and M4 were estimated using the population PK models. Though none of the covariate factors evaluated on bendamustine PK model parameters reached statistical signiWcance, exposure estimates were stratiWed by covariate categories in order to assess the presence of trends for exposure diVerences between groups. No notable diVerences between groups were present for sex, age, or race. A visual trend for increasing exposure with increasing BSA was observed, with maximum diVerences in median values across quartiles of BSA being approximately 30% for both AUC and C max .
No patients with PK data were classiWed as having moderate or severe hepatic dysfunction or severe renal dysfunction. Median bendamustine AUC and C max showed little diVerence between the normal (N = 52) and mild (N = 26) hepatic dysfunction groups or between the normal (N = 47), mild (N = 23), and moderate (N = 8) renal dysfunction groups. This assessment supports the lack of signiWcance of mild hepatic dysfunction and mild or moderate renal dysfunction as a predictor of PK variability.
Exposure-response data
The eYcacy and safety analysis datasets consisted of data from a total of 80 patients (78 patients with bendamustine concentrations and 2 patients with metabolite concentrations only). A total of 78 patients had bendamustine exposure estimates, 77 patients had M3 exposure estimates, and 74 patients had M4 exposure estimates. A total of 71 patients had each of the analytes, and thus a composite AUC and C max . Patient characteristics for the eYcacy/safety dataset are presented in Table 3 .
EYcacy results
Of the 80 patients in the exposure-response analysis of eYcacy, 68 patients (85%) were responders after treatment with bendamustine. No exposure measure was a signiWcant predictor of responder status.
No relationship between DR and exposure was identiWed by exploratory graphical or Kaplan-Meier analysis. Exploratory graphical analyses suggested an initial trend for a relationship between PFS and bendamustine C max up to 60 weeks, and between bendamustine AUC, composite AUC, and composite C max up to 30 weeks, followed by no diVerence. However, Kaplan-Meier analysis resulted in no statistically signiWcant relationship between PFS and any exposure measure. The Kaplan-Meier plot for progressionfree survival based on cycle 1 bendamustine AUC separated by AUC values above and below the median value is shown in Fig. 5 (P value = 0.3025).
Safety results
Across all cycles of the study, there were 237 patient cycles with the occurrence of grade 3 or 4 neutropenia and 179 patient cycles without grade 3 or 4 neutropenia. The mean (SD) AUCs in patients with and without neutropenia were 13,547 (5,261) ng £ h/mL and 12,459 (3,654) ng £ h/mL. Thus, though neutropenia occurred frequently even with some use of cytokines, there did not appear to be a strong relationship with the exposure level to bendamustine.
A total of 45 patients (56%) had at least one occurrence of fatigue during the treatment period; however, no exposure measures or patient factors were statistically signiWcant predictors of the probability of fatigue.
A total of 59 patients (74%) had at least one occurrence of nausea during the treatment period. The majority of the patients (64 of 80 patients) received antiemetic therapy (primarily 5-HT3 receptor antagonists) during the trial. This high percentage of prophylactic antiemetic use precluded statistical assessment of the inXuence of this factor on the relationship between bendamustine exposure and nausea in this analysis. Bendamustine C max was a statistically signiWcant (P value = 0.013) predictor of the probability of nausea. The relationship between the predicted probability of nausea and bendamustine C max is shown in Fig. 6 , upper panel. As bendamustine C max increases, the predicted probability of nausea increases. The odds ratio of 1.00043 (95% CI = 1.00000, 1.00088) indicates that for a 100-unit (ng/ mL) increase in bendamustine C max , the probability of a nausea adverse event is 1.043 times more likely. For a patient with a C max value of 5,001.20 ng/mL (25th percentile), the probability of nausea is 0.68, whereas, a patient with a C max value of 6,567.20 ng/mL (75th percentile) would have a probability of nausea of 0.81. The HosmerLemeshow goodness-of-Wt statistic was 13.01 with 8 degrees of freedom (P value = 0.1115). The area under the receiver-operator characteristic (ROC) curve was 0.63, indicating an adequate Wtting and marginally predictive model.
A total of 25 patients (31%) had at least one occurrence of vomiting during the treatment period. Sex and the number of prior treatment courses (1-10) were statistically signiWcant predictors of the probability of vomiting. No exposure measures were signiWcant predictors of vomiting. Due to the high percentage of patients that received prophylactic antiemetics, the inXuence of this factor could not be statistically assessed. The predicted probability of vomiting versus the number of prior treatment courses with observed probabilities from each number of prior treatment courses is shown in Fig. 6 , lower panel. As the number of prior treatment courses increases, the probability of vomiting decreases. The observed probability of vomiting for each number of prior treatment courses generally corresponds with the model-based predicted probabilities. Females were also shown to have a higher probability of vomiting when compared to males. When only grade 3 or 4 level thrombocytopenia, fatigue, or nausea were considered, there was no signiWcant diVerences in bendamustine exposure (AUC) between patients experiencing these toxicities at grade levels 3 or 4, and those patients without occurrence these events. There were no patients with grade 3 or 4 vomiting that had available PK information.
Discussion
Based on the PK proWle of bendamustine, a dose of 120 mg/m 2 produced C max concentrations of approximately 6 g/mL in these patients with NHL. Ex vivo studies have previously demonstrated that the median lethal dose for bendamustine in CLL cells ranges from 4.3 to 7.4 g/mL [13] . These ex vivo studies also demonstrated that high concentrations of bendamustine are more eYcient than prolonged exposure and that a single exposure to bendamustine was suYcient to initiate apoptosis in cancer cells, with the proportion of dead cells increasing over 72 h.
Individual patient exposures were estimated for bendamustine and its metabolites using the Wnal population PK models. In order to address clinical pharmacology labeling issues, the exposures were summarized across categories of patient factors, laboratory measures, and special populations to evaluate potential diVerences in estimated exposures between groups. Mild or moderate renal impairment, mild hepatic impairment, or diVerences in age or sex did not aVect systemic exposure to bendamustine. These results are limited, however, and therefore bendamustine should be used with caution in patients with mild or moderate renal impairment, or mild liver impairment [23] . Conclusions regarding the eVect of race/ethnicity on exposure to bendamustine in this analysis cannot be drawn due to the limited available data.
Across the full range of data, a trend for increasing exposure with increasing BSA was observed suggesting that BSA-based dosing did not normalize exposures. However, the relationship between AUC and BSA was Xat over 80% of BSA values suggesting that BSA-based dosing is appropriate to achieving a consistent exposure level. Given the narrow range of BSA-based doses in this trial, a deWnitive conclusion cannot be drawn regarding the eVect of BSAbased dosing on bendamustine exposure based on the present data.
The lack of a statistically signiWcant relationship between PFS and exposure may not be surprising since there was a high degree of response across a narrow range of exposures. The BSA-based dosing utilized in this study achieved the intent of targeting an exposure associated with a high incidence of therapeutic response across patients. Perhaps an exposure-response relationship could not be characterized because the exposures were clustered within the eVective range. Nausea was the only safety or eYcacy endpoint that was signiWcantly related to bendamustine exposure, with the probability of nausea increasing as bendamustine C max increased. This conclusion assumes the presence of concurrent prophylactic antiemetic use as most patients received this therapy during the trial. Perhaps it is not surprising that an exposure-response relationship for fatigue was not observed, since fatigue occurs commonly in patients with cancer, and its complex etiology makes it diYcult to determine consistent correlates of fatigue in this patient population [24] . The ability of these analyses to detect potential exposure-response relationships for safety endpoints was limited, however, by the narrow range of exposures resulting from administration of BSA-based dosing of bendamustine at a single dose level.
Female patients were more likely to develop vomiting than male patients. This Wnding is consistent with previous reports indicating that female gender is a risk factor for chemotherapy-induced nausea and vomiting [25, 26] . As the number of prior treatment courses increased, the predicted probability of vomiting decreased. The reason for this Wnding is unclear, but is potentially related to more optimal antiemetic use based on prior experience, or to chemotherapy dose adjustment.
In summary, despite many years of clinical experience with bendamustine, only limited PK information has been published. This paper describes the population PK proWle of bendamustine, and its active metabolites in patients with NHL. No patient factors (including BSA) or laboratory measures were found to signiWcantly inXuence the PK of bendamustine. In addition, estimation of individual patient exposures allowed for the evaluation of the exposureresponse relationships for safety and eYcacy of bendamustine. The occurrence of nausea was related to bendamustine C max , such that an increasing C max results in an increased predicted probability of nausea, even in the presence of antiemetic therapy. No exposure-response was evident for measures of eYcacy (responder status and progression-free survival), and though they occurred frequently, no exposure-response relationships were found for the safety measures neutropenia, fatigue, or vomiting. Sex and prior treatment courses were statistically signiWcant predictors of the occurrence of vomiting. Overall, the results of these analyses facilitate understanding of the PK and exposureresponse relationships for bendamustine demonstrated during clinical development for NHL.
